Middle East and Asia Pacific Antibody Drugs Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-10　·　151 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 70,457.6 Mn
2033 年預估規模: USD 164,642.7 Mn
年複合成長率 CAGR: 12.7%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-10頁數 151報告編號 CMI4952

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Middle East and Asia Pacific Antibody Drugs Market, By Type (Monoclonal Antibody, Polyclonal Antibody, Bispecific Antibody, Biosimilars, Single Domain Antibody, CAR-T, Anti-idiotype Antibody), By Disease Indication (Oncology, Neurology, Autoimmune Disorders, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (Middle East & Asia Pacific)

報告摘要

Antibody drugs are established first-line treatment modalities for a range of cancer and other diseases. On the basis of type, the Middle East and Asia Pacific antibody drugs market is segmented into Monoclonal Antibody, Polyclonal Antibody, Bispecific Antibody, Biosimilars, Single Domain Antibody, CAR-T, and Anti-idiotype Antibody. Monoclonal Antibody are laboratory-produced antibodies designed to recognize and bind to specific receptors found on the surface of cells. Monoclonal Antibody are used in the diagnosis and treatment of various diseases including some types of cancer. Polyclonal antibodies are a heterogeneous mix of antibodies derived from the immune response of multiple B-cells, in which each one recognizes a different epitope on the same antigen. Polyclonal antibodies are composed of a mixture of antibodies that represent the natural immune response to an antigen. Biosimilar Monoclonal Antibody (mAbs) are part of the biosimilar family. They are large, complex proteins used by the immune system to identify and neutralize foreign bodies such as bacteria, viruses, and others, and are usually administered in the treatment of diseases such as cancer or rheumatoid arthritis. Market Dynamics The high prevalence of chronic diseases such as cancer, multiple sclerosis, asthma, rheumatoid arthritis, psoriasis, and others is expected to drive the Middle East and Asia Pacific antibody drugs market growth in the forecast period. For instance, according to the Cancer Country Profile 2020 published by the World Health Organization (WHO), the total number of cancer cases in 2018 in Bahrain was 1,048 with 603 deaths. Moreover, as per the information provided in an article published in the Journal of Clinical Medicine in 2021, Saudi Arabia has the highest prevalence of non-communicable diseases (NCDs) such as cancer, cardiovascular disease, and others, which account for 73% of the country's mortality. Key features of the study • This report provides an in-depth analysis of the Middle East and Asia Pacific antibody drugs market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the Middle East and Asia Pacific antibody drugs market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies • Key companies covered as a part of this study include Novartis AG, Amgen, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson Private Limited, Abbvie, Inc., Eli Lilly and Company, GlaxoSmithKline plc., Daiichi Sankyo Company, Limited, Celltrion Healthcare Co., Ltd., Mylan N.V., Boehringer Ingelheim International GmbH., Biocon, and Merck & Co., Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The Middle East and Asia Pacific antibody drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Asia Pacific antibody drugs market Market Segmentation • By Type o Monoclonal Antibody o Polyclonal Antibody o Bispecific Antibody o Biosimilars o Single Domain Antibody o CAR-T o Anti-idiotype Antibody • By Disease Indication o Oncology o Neurology o Autoimmune Disorders o Others • By Distribution Channel o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • By Region o Middle East  Kingdom of Saudi Arabia  UAE  Israel  Iran  Jordan  Turkey  Qatar  Rest of Middle East o Asia Pacific  South East Asia  The Philippines  Malaysia  Singapore  Thailand  Vietnam  Rest of South East Asia  Taiwan  Hong Kong  Macau  Japan  South Korea  India  Australia  China  Rest of Asia Pacific • Key Players o Novartis AG o Amgen, Inc. o Hoffmann-La Roche Ltd o Pfizer Inc. o Johnson & Johnson Private Limited o AbbVie o Eli Lilly and Company o GlaxoSmithKline plc. o Daiichi Sankyo Company o Limited, Celltrion Healthcare Co., Ltd. o Mylan N.V. o Boehringer Ingelheim International GmbH. o Biocon o Merck & Co., Inc.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Type  Market Snapshot, By Disease Indication  Market Snapshot, By Distribution Channel  Market Snapshot, By Region  Market Opportunity Map 3. Middle East and Asia Pacific Antibody Drugs Market Insights o Drivers o Restraints o Opportunity o Impact Analysis o Pipeline Analysis o Market Trends o Product Launches o Key Developments o Regulatory Scenario o Government Initiatives o Overview of Clinical and Commercial Manufacturing of Therapeutic Antibody Drugs o Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation o Collaborations & Agreements o Epidemiology o PEST Analysis 4. Middle East and Asia Pacific Antibody Drugs Market, By Type, 2026 – 2033 (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Monoclonal Antibody  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Polyclonal Antibody  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Bispecific Antibody  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Biosimilars  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Single Domain Antibody  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o CAR-T  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Anti-idiotype Antibody  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) 5. Middle East and Asia Pacific Antibody Drugs Market, By Disease Indication, 2026 – 2033 (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Oncology  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Neurology  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Autoimmune Disorders  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) 6. Middle East and Asia Pacific Antibody Drugs Market, By Distribution Channel, 2026 – 2033 (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) 7. Middle East and Asia Pacific Antibody Drugs Market, By Region, 2026 – 2033 (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Region at Trends o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn)  Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2026–2033, (USD Mn) o Kingdom of Saudi Arabia  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o UAE  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Israel  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Iran  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Jordan  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Turkey  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Qatar  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Rest of Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn)  Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2026–2033, (USD Mn) o South East Asia  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o The Philippines  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Malaysia  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Singapore  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Thailand  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Vietnam  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Rest of South East Asia  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Taiwan  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Hong Kong  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Macau  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Japan  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o South Korea  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o India  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Australia  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o China  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) o Rest of Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026–2033, (USD Mn) 8. Competitive Snapshot o Company Profiles  Novartis AG o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Amgen, Inc. o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Hoffmann-La Roche Ltd o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Pfizer Inc. o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Johnson & Johnson Private Limited o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  AbbVie o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Eli Lilly and Company o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  GlaxoSmithKline plc. o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Daiichi Sankyo Company, Limited o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Celltrion Healthcare Co., Ltd. o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Mylan N.V. o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Boehringer Ingelheim International GmbH. o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Biocon o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies  Merck & Co., Inc. o Company Highlights o Product Portfolio o Key Highlights o Financial Performance o Market Strategies 9. Section o Research Methodology o About us

提及公司

Novartis AGAmgen, Inc.Hoffmann-La Roche LtdPfizer Inc.Johnson & Johnson Private LimitedAbbVieEli Lilly and CompanyGlaxoSmithKline plc.Daiichi Sankyo CompanyLimited, Celltrion Healthcare Co., Ltd.Mylan N.V.Boehringer Ingelheim International GmbH.BioconMerck & Co., Inc.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們